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Barth syndrome is an X-linked recessive disorder caused
by the tafazzin (TAZ) gene mutations and includes
dilated cardiomyopathy (DCM) with left ventricular non-
compaction, neutropenia, skeletal myopathy, abnormal
mitochondria and 3-methylglutaconic aciduria. Dilated
cardiomyopathy with left ventricular non-compaction trans-
mitted as an autosomal dominant condition has also been
associated with LIM domain-binding 3 (LDB3) gene defects.
We describe a family in which the 12-year-old proband had
left ventricular non-compaction and DCM. His mother had
five miscarriages, two other sons who died in infancy, and a
healthy son and daughter. The proband showed left
ventricular non-compaction–DCM, skeletal myopathy,
recurrent oral aphthous ulcers and cyclic neutropenia. The
DCM progressively improved with age; medical therapy was
discontinued at 5 years of age. At present, left ventricular
function is normal and arrhythmias are absent. Magnetic
resonance imaging documented left ventricular non-com-
paction. However, oral aphthous ulcers and cyclic neutro-
penia have recurred. In the proband we identified two novel
mutations, one of maternal origin in the TAZ gene
(p.[Glu202ValfsX15]) and one of paternal origin in the
LDB3 gene (p.[Thr350Ile]). The mother, brother and father
are healthy; although the latter two show prominent left
ventricle trabeculation without dysfunction. Expression
studies of TAZ and LDB3 genes were conducted in family
members and controls. In the proband, brother and father,
LDB3 expression was similar to control cases. TAZ and LDB3
expression progressively declined with age in control both
blood and myocardial samples. However, an endomyocar-
dial biopsy performed in the proband at 6 months of age,
showed significantly lower TAZ and LDB3 expression than in
age-matched myocardial controls. We believe that the
clinical, genetic and expression data support the hypothesis
that tafazzins are essential during fetal and early post-natal
life.  2007 Wiley-Liss, Inc.
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INTRODUCTION
Barth syndrome (#OMIM*302060, BTHS) [Barth
et al., 1981, 1983] is an X-linked recessive condition
that includes dilated cardiomyopathy (DCM),
neutropenia, skeletal myopathy, abnormal mito-
chondria and 3-methylglutaconic aciduria [Kelley
et al., 1989, 1991; Barth et al., 2004 (Review)]. Barth
syndrome maps to Xq28 [Bolhuis et al., 1991] and
is caused by mutations of the TAZ gene,
(OMIM*300394) [Bione et al., 1996], which codes
for tafazzin, an acyltransferase acting in the remodel-
ing of cardiolipin in the inner mitochondrial
membrane [Neuwald, 1997; Vreken et al., 2000;
Valianpour et al., 2002].
The DCM in Barth syndrome is characterized by
non-compaction of the left ventricle, which may also
occur as an isolated X-linked recessive trait in carriers
of TAZ mutations [Bleyl et al., 1997]. Autosomal
dominant familial left ventricular non-compaction,
both isolated (OMIM*604169) and associated
with congenital heart defects (OMIM*606617), has
recently been mapped to 18q12.1-q12.2 where a
missense mutation (p.[Pro121Leu]) has been identi-
fied in the Alpha Dystrobrevin gene (DTNA,
OMIM*601239) [Ichida et al., 2001]. An additional
locus has been mapped at 10q22.2-q23.3, and
missense mutations have been identified in the
LIM Domain-Binding 3 (LDB3, OMIM*605906) gene
in families with DCM and left ventricular non-
compaction [Vatta et al., 2003].
We describe a family in which the proband was
diagnosed with Barth syndrome and was found to
carry a maternal TAZ gene mutation and a paternal
LDB3genemutation.TAZ and LDB3 geneexpression
were evaluated in the RNA from peripheral blood
leukocytes and myocardial samples of the proband
and control DCM patients. Only the quantitative
expression of the TAZ gene in the endomyocardial
biopsy obtained from the proband at 6 months of age
showed values lower than controls.
MATERIALS AND METHODS
Family Pedigree and Clinical Evaluation
The family historywasobtained from theparents of
the proband (Fig. 1A), and supplemented by clinical
(n¼ 2) and autopsy (n¼ 1) records of the deceased
brothers of the proband. Both parents, brother, sister
and maternal aunt (one of two) underwent clinical,
electrocardiographic and echocardiographic evalua-
tion and serum creatinine phosphokinase (sCPK)
testing.
Cardiac magnetic resonance imaging at 1.5-T
(Symphony, Siemens Medical Solutions, Erlangen,
Germany)wasperformedon theproband, father and
brother. Steady-state free precession cine images
were acquired in long- and short-axis views and
short-axis to visualize all segments in accordance
with American Heart Association recommendations
[Cerqueira et al., 2002]. The ratio of non-compacted
to compacted myocardium (NC/C) was calculated in
diastole. We considered a NC/C ratio greater that
2.3 for at least three segments (apex not included)
as appropriate criterion for left ventricular non-
compaction diagnosis.
FIG. 1. A: family pedigree; (B) endomyocardial biopsy performed at the age of 6-month showing non-specific myocyte damage with myofibrillar loss and interstitial
fibrosis; (C and D) electron micrographs of the endomyocardial biopsy showing mitochondrial proliferation (areas included within the white marks) and sarcomeric
loss (arrow); (uranyl acetate, lead citrate).
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Genotyping
TAZ and LDB3 genes were analyzed by direct
bidirectional sequencing of the amplicons contain-
ing the corresponding coding and flanking regions
using the BigDye Terminator Cycle sequencing kit V
3.1 (Applied Biosystems, Foster City, CA) on an ABI
3130 Xl Genetic Analyzer, following the manufac-
turer’s directions. For the LDB3 gene we used the
primers reported by Vatta et al. [2003]. Reference
sequences are: for the TAZ gene the NM_000116
(NCBI) and the ENSG00000102125 (Ensembl); for
the LDB3 gene the NM_007078 (NCBI) and the
ENSG00000122367 (Ensembl); NM_007078 refers to
the coding sequence of the C/Z4 cardiac isoform,
which contains the exons 1–4, 7, 8, 10–16.
Controls
For TAZ and LDB3 gene mutations, controls were
constituted of 53 and 100 DCM (including 12 left
ventricular non-compaction dilated cardiomy-
opathy) respectively. We included 120 additional
normal controls for the LDB3 mutation. Of the
53 controls for TAZ gene mutations, three were
commercially available pre-natal DNAs (Stratagene
and ECACC), one postnatal sample was from a heart
excised at transplantation at 20 days of age for
hypoplastic left heart syndrome and 49 are DCM. The
same 53 cases were used as controls for TAZ and
LDB3 gene expression in the peripheral blood.
Controls for myocardial gene expression consisted
of myocardial samples for 32 of the 53 above cases
with TAZ and LDB3 negative gene screening: the
three previously-mentioned prenatal samples and
29 hearts excised at transplantation in patientswhose
age ranged from 20 days to 55 years.
TAZ and LDB3 Quantitative Gene
Expression Profiles
Expression profiling of TAZ and LDB3 genes were
carried out by real time quantitative PCR (Q-PCR) and
the corresponding values calculated for each sample
with respect to the housekeeping gene by means of
the comparative method described by Livak and
Schmittgen [2001]. Total RNA was extracted from
peripheral blood and myocardial samples on the ABI
6100 platform according to the manufacturer’s speci-
fications; quality was checked on agarose gel. RNA
was converted to cDNA with random hexamers (High
Capacity cDNA Archive Kit, Applied Biosystems).
Two specific sets of Assay-On-Demand (Applied
Biosystems), Hs00900287_g1 and Hs00951222_m1,
were used for the Q-PCR amplification of the TAZ and
LDB3 genes. The HPRT (Hs99999909_m1) was
selected as housekeeping gene. Exact location of
primers and probes is reported at the Applied
Biosystems url. Briefly, three replicates were made
from each sample and run on the ABI 7900 HT
platform (Applied Biosystems). Data were extracted
and analyzed with STATISTICA (StataSoft).
Protein Modeling
To simulate the potential modifications induced by
the mutations on the primary structure of the protein,
we generated sphere-based models of the TAZ and
LDB3 proteins using the PyMol software. We also
assessed the half-life ofmutatedproteins bymeans of
a modification of the N-terminal rule as from the SNP
effect database.
Web Resources
Web resources used in the study include:
(a): www.ncbi.nlm.nih.gov and www.ensembl.org
for the reference gene sequences; (b) www.applied-
biosystems.com (supplies for genotyping and gene
expression); (c) www.stratagene.com (supplies for
tissue DNA and RNA analysis); (d) www.ecacc.
org.uk/ (supplies for tissue DNA and RNA analysis);
(e) the PyMol software: http://pymol.sourceforge.
net/; (f) the SNP effect database: http://snpeffect.
vib.be/; (g) the gene ontology: www. geneontology.
org; (h) the mutation nomenclature: www. hgvs.org/
mutnomen/.
RESULTS
Proband’s History
The proband (Fig. 1, III:10) is a 12-year-old male
last-born to non-consanguineous parents. He was
first diagnosed with DCM at 3 months of age because
of failure to thrive and dyspnea. His chest X-ray
showed cardiomegaly and the echocardiogram
documented left ventricle dilation with severe
systolic dysfunction (ejection fraction¼ 20–25%),
which required treatment with inotropic agents,
ACE-inhibitors, and diuretics. Metabolic screening
at 6 months of age excluded fatty acid beta-oxidation
defects and mitochondrial oxidative metabolic dis-
orders. The endomyocardial biopsy excluded myo-
carditis and showed myofibril loss and interstitial
fibrosis (Fig. 1B). Ultrastructural study showed
mitochondrial proliferation and sarcomeric derange-
ment (Fig. 1C,D). Echocardiography showed biven-
tricular hypertrophy, hypokinesia of the septum and
posterior left ventricle wall, mild mitral and tricuspid
valve regurgitation and mild pericardial effusion.
Laboratory data are reported in Table I. Immunoen-
zymatic serological studies for human Cytomegalo-
virus, Toxoplasma gondii, Rubella, and Herpesvirus
2 were negative. Since then, left ventricle function
has progressively improved over the years, becom-
ing subclinical and normal. Medical therapy was
discontinued at 5 years of age.
The proband came to our clinical attention at age
11 years. In his past history we noted delayed motor
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milestones, poor physical performance attributed to
his prior cardiacproblems, normal neurological
development, and recurrent stomatitis. He showed
generalized joint hypermobility, aphthous stomatitis,
reduced muscular mass of inferior limbs, muscle
weakness on testing and exertion fatigue. Plasma
cholesterol and neutrophils were lower than normal.
Serum aldolase and lactate levels were slightly
elevated (Table I). One fasting measurement of
3-methylglutaconic aciduria tested negative; further
tests are planned at intervals of 6 months after leucine
loading. The electromyography evaluation (EMG)
showed a minimal increase in polyphasic motor unit
potentials consistent with very mild primitive muscle
impairment interpreted as due to the lack of muscle
activity. His electrocardiogram (ECG) showed
sinus rhythm and normal conduction intervals.
Ergometric testing was interrupted at 25 W (heart
rate¼ 160 bpm). ECG Holter monitoring for 24 hr did
not record arrhythmias. T-wave alternans was
absent. Echocardiography documented normal left
ventricle systolic function, but increased trabecula-
tion of the left ventricle (Fig. 2A,B) [Jenni et al., 2001].
Cardiac magnetic resonance imaging showed iso-
lated left ventricular non-compaction, lateral wall,
with a NC/C 2.3 in five segments (apex not
included) (Fig. 2C,D) [Petersen et al., 2005].
Family History
The mother had a brother who had died at the age
6 months of unknown causes (Fig. 1). Two of the
mother’s sisters and one brother are alive and
healthy; one sister (II:4) carries the TAZ mutation.
The mother of the proband had ten pregnancies
including five miscarriages and five liveborn infants.
Two boys died, survived by a healthy girl, a healthy
boy and the proband (Fig. 1A). One (III:3) of the
deceased boys died at 6 months of cardiac failure
clinically diagnosed as acute myocarditis (no post-
mortem examination). We traced an ECG that
showed left ventricular hypertrophy and sinus
tachycardia (heart rate¼ 160 bpm). The second
boy (III:5) died on the second day of life and
autopsy reported endocardial fibroelastosis (autopsy
samples could not be traced). The father (II:1),
brother (III:8) and sister (III:9) were described as
healthy.
Molecular Genetics Evaluations
Basedon the admissiondiagnosis of left ventricular
non-compaction, we screened both the TAZ gene
(because of the family and clinical history, the left
ventricular non-compaction and male sex) and LDB3
gene (because of the left ventricular non-compac-
tion) in which we had previously found mutations
associated with both DCM and left ventricular non-
compaction [Pilotto et al., 2005]. The child was found
to carry a novel 4 bp deletion in exon 8 of the TAZ
gene (p.[Glu202ValfsX15]) and a missense hetero-
zygous mutation in exon 10 of the LDB3_iC/Z4
cardiac isoform (p.[Thr350Ile]). The Thr residue at
position 350 is highly conserved in mammals
(Fig. 3D). Screening of the maternal relatives for the
TABLE I. Serial Biochemical Data* Recorded in the Proband With Barth Syndrome
Age 6 months 6 months 7 months 12 months 10 years 12 years
Leukocytes (103/ml) 9.9 11 10.4 6.82 7.32 4.5
Lymphocytes (103/ml) 7.7 6.38 7.28 3.77 3.37 2.6
Neutrophils (103/ml) 1.98 4.4 3.12 0.3 1.84 0.7
Monocytes (103/ml) 0.2 0 0 1.95 1.15 1
Lactic acid (mg/dl) 24.1 36.1
Piruvate (mg/dl) 0.46 0.52
Cholesterol (mg/dl) 116 107
Aldolase (mU/ml) 15
Creatine phospho-kinase (mU/ml) 82
Bolded values are abnormal.
*Reference values in ‘Nelson, Textbook of Pediatrics’ (17th edition; 2004, Saunders; http://home.mdconsult.com/das/book/64524402-2/view/1175).
FIG. 2. Echocardiographic study (A: apical four-chamber view; B: para-
sternal short-axis view) showing themarked trabeculationof the left ventricle of
the proband (III:10). Cardiac magnetic resonance study (C–I) confirmed and
better highlighted (C, E; arrows) the trabeculation pattern.
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TAZ gene revealed that the mother (II:2) carried the
TAZ gene mutation without ECG and echocardio-
graphy abnormalities. The father (II:1) and brother
(III:8) of the proband carried the LDB3 gene
mutation (Fig. 3A–C) accompanied by left ventricu-
lar trabeculation on cardiac magnetic resonance
imaging. However, the NC/C ratio between the
thickness of non-compacted and compacted myo-
cardial layers in diastole did not reach the American
College of Cardiology requirements for the diagnosis
of left ventricular non-compaction [Petersen et al.,
2005] (Fig. 4A,B). Left ventricular function was
normal at both echocardiography and cardiac
magnetic resonance. The proband’s sister (III:9) did
not carry either mutation and showed normal
imaging and clinical findings. A maternal aunt (II:4)
is a healthy carrier of the p.[Glu202ValfsX15] with a
normal cardiological evaluation. Her two brothers
(II:3 and II:6) did not inherit the mutation.
Gene Expression Profiling
Before performing the gene expression experi-
ments, we assessed the RNA quality of all of the
samples (including those extracted from paraffin
embedded tissues) on agarose gel using the 18S/28S
ratios as quality standard. The effects of the muta-
tions on the mRNA decay and on age-related gene
regulation were tested on the TAZ and LDB3 mRNAs
by means of Q-PCR. Figure 5 shows the results in
control samples and in the proband (III:10), father
(II:1) and mother (II:2). In the peripheral blood
sample of the proband at 12 year of age, expression
levels of TAZ and LDB3 respectively were non-
significantly lower and higher than control
values (TAZ: 12 1.21 vs. 22 0.66, n.s.; LDB3:
21.7 0.32 vs. 19 0.52, n.s.). TAZ and LDB3mRNAs
in maternal and paternal peripheral blood were
expressed at levels similar to those of controls.
In the myocardium, an age-dependent decrease of
TAZ expression was observed in our 32 control
samples. LDB3 showeda similar but less pronounced
trend (Fig. 5). Correlations (r2) between expression
in blood and myocardial samples were 0.9775 and
0.9706 for TAZ and LDB3 genes, respectively.
Myocardial expression in the endomyocardial
biopsy performed on the proband at 6 months was
significantly lower than in age-matched controls
(TAZ 212 4.3 vs. 300 15.4; P< 0.01; LDB3
182 5.98 vs. 198 9.56; P< 0.05).
DISCUSSION
This is the first case of Barth syndrome associated
with compound heterozygous mutations, one in
exon 8 of the TAZ gene (p. [Glu202ValfsX15])
FIG. 3. Electropherograms showing the two mutations. A: Maternal hetero-
zygous TAZ mutation; (B) hemizygous TAZ gene mutation in the proband; (C)
heterozygous LDB3 mutation in the proband; (D) amino acid alignments
showing the evolutionarily conservation in mammals of the p.[Thr350Ile]
mutation in LDB3 gene.
FIG. 4. The cardiac magnetic resonance of father (II:2; A) and brother (III:8;
B) of the proband showed trabeculation of the left ventricle that did not reach
the trabeculated/non-trabeculated ratio necessary for the magnetic resonance
diagnosis of left ventricular non-compaction.
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and one in exon 10 of the LDB3 gene C/Z4 isoform
(p. [Thr350Ile]). The significance of this combination
is uncertain. The clinical markers are typical of Barth
syndrome and the disease-causing gene is TAZ
because only the hemizygous p.[Glu202ValfsX15]
mutation carrier is affected, while the two hetero-
zygous carriers of the LDB3 gene defect are clinically
and instrumentally healthy, only showing increased
trabeculation of the left ventricle whose extent
does not satisfy the criteria for left ventricular non-
compaction [Jenni et al., 2001; Petersen et al., 2005].
Although TAZ mutations in exon 8 were initially
thought to be associated with potentially benign
phenotypes [D’Adamo et al., 1997], later studies
showed that carriers of exon 8 mutations were
characterized by poor prognosis [Johnston et al.,
1997].
The role of the LDB3 gene mutation is unclear. This
mutation was absent in a large series of normal and
DCM controls; it is evolutionarily conserved in
mammals, and does not alter the predicted structure
of the protein (Fig. 6). The mutation occurs in
exon 10, which is expressed in the human myocar-
dial C/Z2 and C/Z4 isoforms. It only predicts a
decreased turnover of the protein, in wild-type from
2,400 to 2,900 min of the mutant (http://snpeffect.
vib.be/). Heterozygous LDB3 gene mutations have
recently been associated with left ventricular non-
compaction [Vatta et al., 2003], but we have found
LDB3 gene mutations in familial idiopathic dilated
cardiomyopathy with normal trabeculation [Pilotto
et al., 2005]. From the phenotypic expression in this
family, the LDB3 gene mutation seems to be a
modifier polymorphism: the potential contribution
could be to the increased trabeculation of the left
ventricle. We planned regular clinical monitoring of
the two heterozygous LDB3 carriers.
Based on the quantitative gene expression data,
the hypothesis of an age-related function of the
tafazzins (with a major role in fetal and early
postnatal life, and then progressive substitution of
the functions they code inpostnatal life) proposedby
D’Adamo et al. [1997] is plausible. We tested
this hypothesis because the proband’s cardiomyo-
pathyprogressively improvedwith age until function
was normal. In our 53 controls we found a
progressive decline of TAZ expression in the RNA
from peripheral white cells. Although RNA levels of
TAZ in peripheral blood white cells may not reflect
myocardial expression, an age-related decrease in
TAZ expression was also confirmed in 32 corre-
sponding hearts shown by sequencing not to carry
TAZ and LDB3 gene mutations. The similar trend
observed for LDB3 expression suggests that also this
gene plays a role in prenatal and neonatal life.
Both genes act in the Gene Ontology category of
FIG. 5. Expression levels of TAZ and LDB3 genes normalized to the HPRT housekeeping gene (y-axis) with respect to the age (x-axis). Solid black squares: TAZ gene;
open circles: LDB3 gene. A: Heart tissue. The red and blue dots indicate the TAZ and LDB3mRNA levels in the EMB performed at 6 months of age in the proband (III:10).
B: peripheral expression of TAZ (red dots) and LDB3 (blue dots) genes in the proband (III:10) and his parents (II:1 and II:2) showing levels similar to those of age-
matched controls. C: expression levels with standard deviation for the analyzed peripheral blood and myocardial samples. D: myocardial (6 months of age) and
peripheral (12 years of age) expression levels of TAZ and LDB3 genes in the proband, and peripheral values in his parents.
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Development Process (GO number BP00193) and
are expressed in fetal and postnatal life. However,
our current data do not prove that they function
linearly. To assess this hypothesis further experi-
ments are needed with animal models and morpho-
lino antisense oligonucleotides. Therefore, our data
do not explain why but document an age-related
decline in expressionof both genes. As for peripheral
LDB3 gene expression in mutation carriers, values
were similar to those measured in controls. Only the
cardiac biopsy sample of the proband at 6 months of
age showed LDB3 and TAZ expression levels lower
than age-matched controls.
An open clinical question is the prognosis of this
child, who had a very severe cardiac phenotype at
onset, and now shows normal cardiac function. His
major current clinical limitation is muscle weakness
whose severity is difficult to estimate because the
child has progressively reduced his physical activity.
His ergometric stress test was interrupted at 25 W
because of exhaustion, but at a maximal heart rate of
160 bpm. His sCPK levels were within the normal
ranges in two different measurements. His parents
refused invasive procedures including muscle
biopsy. Currently, genotype data add little to
prognostic stratification and patients with Barth
syndrome may show variability in the severity of
their phenotype within the same family. The risk of
arrhythmias can be expected to increase in adoles-
cence [Spencer et al., 2005]. In addition to the
underlying pathological substrate of DCM, Spencer
et al. revised the pathogenetic hypothesis and
suggested that cardiac rhythm disturbances could
be triggeredby autonomic [La Rovere et al., 2003] and
mitochondrial dysfunction [Liu et al., 1998]. The risk
of arrhythmias seems to be independent of the
FIG. 6. Stereo representations of lateral (A and B) and upper (C and D) views of the TAZ peptide (residues 198–218); stereo representations of lateral (E and F) and
upper (G and H) views of the LDB3peptide (residues 340–360); A, C, E, G: mutated and B, D, F, H: wild-typepeptides. Arrows indicate the markedly different secondary
structure of TAZ due to the amino acid change and truncation of themutatedpeptide; there are no changes in the secondary structureof LDB3 (E–H).According to theN-
terminal rule, the mutated TAZ and LDB3 genes predict a decreased turnover of the protein in wild-type from 1,400 to 1,700 min of the TAZ mutated protein; and from
2,400 (wild-type) to 2,900 (mutant) of LDB3 (http://snpeffect.vib.be/).
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degree of left ventricle dilation or dysfunction, as
well as of genotype: five patients aged 13–18 years,
carriers of fivedifferentmutations andwithnormal or
mildly depressed left ventricle function, developed
life-threatening ventricular arrhythmias (one fatal)
during adolescence [Spencer et al., 2005]. Risk factors
included a positive family history for sudden death in
one case, torsades de pointes in a second, premature
ventricular complex, positive T-wave alternans and
positive family history for sudden death in a third,
and two syncopal episodes in a fourth. All five
adolescents complained of vasovagal symptoms
[Spencer et al., 2005]. Our patient does not show
arrhythmogenic risk factors and at present there is no
indication for implanting an implantable cardiover-
ter device. However, we do not feel reassured by his
low arrhythmogenic potential because one of the
above five Barth syndrome patients who developed
life-threatening ventricular arrhythmias had no risk
factors, with the exception of vasovagal symptoms
[Spencer et al., 2005]. We have therefore scheduled
regular cardiological monitoring to cover the entire
span of his adolescent life.
In conclusion, this is the first report of compound
heterozygosity (TAZ/LDB3 gene defects) in a patient
with Barth syndrome whose evolution showed a
progressive, spontaneous resolution of the cardio-
myopathy-related left ventricle dysfunction. The risk
of arrhythmia is at present unpredictable and calls for
strict clinical monitoring. The clinical, genetic and
expression data support the hypothesis that tafazzins
are essential during fetal and early post-natal life.
Further studies are necessary to confirm the age-
related TAZ gene expression.
ACKNOWLEDGMENTS
We are grateful to the family members for their
collaboration. This study was supported by grants
‘‘Research on Inherited Cardiomyopathies’’ from the
Cariplo Foundation and the Ministry of Health to the
Foundation IRCCS Policlinico San Matteo.
REFERENCES
Barth PG, Van’t Veer-Korthof ET, Van Delden L, Van Dam K,
van der Harten JJ, Kuipers JRG. 1981. An X-linked mitochon-
drial disease affecting cardiac muscle, skeletal muscle,
and neutrophil leukocytes. In: Busch HFM, Jennekens
FGI, Schotte HR, editors. Mitochondria and muscular
diseases. Beetsterzwaag, The Netherlands: Mefar. p 161–
164.
Barth PG, Scholte HR, Berden JA, Van Der Klei-Van Moorsel JM,
Luyt-Houwen IEM, Van’T Veer-Korthof ETH, Van Der Harten
JJ, et al. 1983. An X-linked mitochondrial disease affecting
cardiac muscle, skeletal muscle, and neutrophil leukocytes. J
Neurol Sci 62:327–355.
Barth PG, Valianpour F, Bowen VM, Lam J, Duran M, Vaz FM,
Wanders RJ. 2004. X-linked cardioskeletal myopathy and
neutropenia (Barth syndrome): An update. Am J Med Genet
Part A 126A:349–354.
Behrman RE, Kliegman RM, Jenson HB. 2004. Nelson textbook of
pediatrics. 17th edition. Saunders.
Bione S, D’Adamo P, Maestrini E, Gedeon AK, Bolhuis PA,
Toniolo D. 1996. A novel X-linked gene, G4.5, is responsible
for Barth syndrome. Nat Genet 12:385–389.
Bleyl SB, Mumford BR, Thompson V, Carey JC, Pysher TJ, Chin
TK, Ward K. 1997. Neonatal, lethal noncompaction of the left
ventricular myocardium is allelic with Barth syndrome. Am J
Hum Genet 61:868–872.
Bolhuis PA, Hensels GW, Hulsebos TJ, Baas F, Barth PG. 1991.
Mapping of the locus for X-linked cardioskeletal myopathy
with neutropenia and abnormal mitochondria (Barth syn-
drome) to Xq28. Am J Hum Genet 48:481–485.
Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S,
Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS.
2002. American Heart Association Writing Group on Myocar-
dial Segmentation and Registration for Cardiac Imaging.
Standardized myocardial segmentation and nomenclature
for tomographic imaging of the heart. A statement for
healthcare professionals from the Cardiac Imaging Committee
of the Council on Clinical Cardiology of the American Heart
Association. Int J Cardiovasc Imaging 18:539–542.
D’Adamo P, Fassone L, Gedeon A, Janssen EAM, Bione S, Bolhuis
PA, Barth PG, Wilson M, Haan E, Orstavik KH, Patton MA,
Green AJ, Zammarchi E, Donati MA, Toniolo D. 1997. The X-
linked gene G4.5 is responsible for different infantile dilated
cardiomyopathies. Am J Hum Genet 61:862–867.
Ichida F, Tsubata S, Bowles KR, Haneda N, Uese K, Miyawaki T,
Dreyer WJ, Messina J, Li H, Bowles NE, Towbin JA. 2001.
Novel gene mutations in patients with left ventricular
noncompaction or Barth syndrome. Circulation 103:1256–
1263.
Jenni R, Oechslin E, Scheider J, Attenhofer Jost C, Kaufmann PA.
2001. Echocardiographic and patho-anatomical characteris-
tics of isolated left ventricular non-compaction: A step
towards classification as a distinct cardiomyopathy. Heart
86:666–671.
Johnston J, Kelley RI, Feigenbaum A, Cox GF, Iyer GS, Funanage
VL, Proujansky R. 1997. Mutation characterization and
genotype-phenotype correlation in Barth syndrome. Am
J Hum Genet 61:1053–1058.
Kelley RI, Clark BJ, Morton DH, Sherwood WG. 1989. X-linked
cardiomyopathy, neutropenia, and increased urinary levels of
3-methylglutaconic and 2-ethylhydracyclic acids (abstract).
Am J Hum Genet 45:A7.
Kelley RI, Cheatham JP, Clark BJ, Nigro MA, Powell BR,
Sherwoodm GW, Sladky JT, Swisher WP. 1991. X-linked
dilated cardiomyopathy with neutropenia, growth retarda-
tion, and 3-methylglutaconic aciduria. J Pediatr 119:738–747.
La Rovere MT, Pinna GD, Maestri R, Mortara A, Capomolla S, Febo
O, Ferrari R, Franchini M, Gnemmi M, Opasich C, Riccardi PG,
Traversi E, Cobelli F. 2003. Short-term heart rate variability
strongly predicts sudden cardiac death in chronic heart failure
patients. Circulation 107:565–570.
Liu Y, Sato T, O’Rourke B, Marban E. 1998. Mitochondrial ATP-
dependent potassium channels: novel effectors of cardiopro-
tection? Circulation 97:2463–2469.
Livak KJ, Schmittgen TD. 2001. Analysis of relative gene
expression data using real-time quantitative PCR and the 2(-
Delta Delta C(T)) method. Methods 25:402–408.
Neuwald AF. 1997. Barth syndrome may be due to an
acyltransferase deficiency. Curr Biol 7:465–466.
Petersen SE, Selvanayagam JB, Wiesmann F, Robson MD, Francis
JM, Anderson RH, Watkins H, Neubauer S. 2005. Left
ventricular non-compaction: Insights from cardiovascular
magnetic resonance imaging. J Am Coll Cardiol 46:101–105.
Pilotto A, Grasso M, Pasotti M, Disabella E, Diegoli M, Lucchelli C,
Porcu E, Repetto A, Campana C, Gavazzi A, Tavazzi L,
Arbustini A. 2005. Cypher/ZASP gene mutations cause
idiopathic dilated cardiomyopathy (IDCM) with poor pro-
gnosis. Poster Session.Po01 (P0237). Clinical genetics.
914 MARZILIANO ET AL.
American Journal of Medical Genetics Part A: DOI 10.1002/ajmg.a
European Human Genetics Conference 2005, Prague: 7-10th
May 2005.
Spencer CT, Byrne BJ, Gewitz MH, Wechsler SB, Kao AC,
Gerstenfeld EP, Merliss AD, Carboni MP, Bryant RM. 2005.
Ventricular arrhythmia in the X-linked cardiomyopathy Barth
Syndrome. Pediatr Cardiol 26:632–637.
Valianpour F, Wanders RJA, Overmars H, Vreken P, van
Gennip AH, Baas F, Plecko B, Santer R, Becker K, Barth
PG. 2002. Cardiolipin deficiency in X-linked cardioskeletal
myopathy and neutropenia (Barth syndrome, OMIM 302060):
A study in cultured skin fibroblasts. J Pediatr 141:729–733.
VattaM,MohapatraB, Jimenez S, SanchezX, Faulkner G, Perles Z,
Sinagra G, Lin JH, Vu TM, Zhou Q, Bowles KR, Di Lenarda A,
Schimmenti L, Fox M, Chrisco MA, Murphy RT, McKenna W,
Elliott P, Bowles NE, Chen J, Valle G, Towbin JA. 2003.
Mutations inCypher/ZASP in patients with dilated cardiomyo-
pathy and left ventricular non-compaction. J Am Coll Cardiol
42:2014–2027.
Vreken P, Valianpour F, Nijtmans LG, Grivell LA, Plecko B,
Wanders RJ, Barth PG. 2000. Defective remodeling of
cardiolipin and phosphatidylglycerol in Barth syndrome.
Biochem Biophys Res Commun 279:378–382.
COMPOUND TAZ/LDB3 MUTATIONS IN BARTH SYNDROME 915
American Journal of Medical Genetics Part A: DOI 10.1002/ajmg.a
